Keros Therapeutics financials
$11.19−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151.0K | $0.00 | $20.1M | $0.00 |
| Gross profit | $244.1M | $3.5M | $151.0K | $0.00 | $20.1M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | — |
| Operating income | $67.6M | -$210.8M | -$167.5M | -$107.7M | -$56.4M | -$46.7M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M | -$45.4M |
| Net margin | 35.7% | −5277.5% | −101319.2% | — | −292.3% | — |
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 |
| EBITDA | $69.1M | -$209.6M | -$166.7M | -$107.0M | -$55.5M | -$46.4M |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M | -$36.9M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M | -$37.2M |
| Diluted shares | 37.9M | 37.4M | 29.4M | 25.2M | 23.3M | 15.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M | $265.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M | $269.4M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M | $7.7M |
| Shareholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M | $261.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology